To our knowledge, there has not yet been an updated systematic review or meta-analysis on relevant RCTs published after February 2019 [39] that compares recurrence and survival-related endpoints between TC and anthracycline-taxane-based chemotherapy across all randomized trials in women with HER2-negative breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.